NY-CAZOO-GROUP
21.3.2022 12:02:11 CET | Business Wire | Press release
Cazoo Group Ltd (NYSE: CZOO) (“Cazoo” or “the Company”), Europe’s leading online car retailer, which makes buying and selling a car as simple and seamless as ordering any other product online, today announced the reporting date for its fourth quarter and fiscal year 2021 results, and the reporting date for its first quarter fiscal year 2022 results.
Fourth Quarter and Fiscal Year 2021
The Company will release its fourth quarter and fiscal year 2021 results before the U.S. stock market opens on Thursday, April 7, 2022. The Company will host a conference call at 8:00 a.m. Eastern Time that day.
Investors and analysts interested in participating in the call are invited to dial 1-877-704-6255, or for international callers, 1-215-268-9947. A webcast of the call will also be available on the investor relations page of the Company’s website at https://investors.cazoo.co.uk .
First Quarter Fiscal Year 2022
The Company will release its first quarter fiscal year 2022 results before the U.S. stock market opens on Tuesday, May 3, 2022. The Company will host a conference call at 8:00 a.m. Eastern Time that day.
Investors and analysts interested in participating in the call are invited to dial 1-877-704-6255, or for international callers, 1-215-268-9947. A webcast of the call will also be available on the investor relations page of the Company’s website at https://investors.cazoo.co.uk .
About Cazoo – www.cazoo.co.uk
Our mission is to transform the car buying and selling experience across the UK & Europe by providing better selection, value, transparency, convenience and peace of mind. Our aim is to make buying or selling a car no different to ordering any other product online, where consumers can simply and seamlessly buy, sell, finance or subscribe to a car entirely online for delivery or collection in as little as 72 hours. Cazoo was founded in 2018 by serial entrepreneur Alex Chesterman OBE, is backed some of the leading technology investors globally and is publicly traded (NYSE: CZOO).
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbour” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of the business of Cazoo may differ from its actual results and, consequently, you should not rely on forward-looking statements as predictions of future events. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (1) realizing the benefits expected from the business combination with Ajax I (the “Business Combination”); (2) achieving the expected revenue growth and effectively managing growth; (3) executing Cazoo’s expansion strategy in Europe; (4) acquiring and integrating other companies; (5) achieving and maintaining profitability in the future; (6) having access to suitable and sufficient vehicle inventory for resale to customers and for Cazoo’s subscription offering and reconditioning and selling inventory expeditiously and efficiently; (7) expanding Cazoo’s subscription offering; (8) increasing Cazoo’s service offerings and price optimization; (9) effectively promoting Cazoo’s brand and increasing brand awareness; (10) expanding Cazoo’s product offerings and introducing additional products and services; (11) enhancing future operating and financial results; (12) acquiring and protecting intellectual property; (13) attracting, training and retaining key personnel; (14) complying with laws and regulations applicable to Cazoo’s business; (15) successfully deploying the proceeds from the Business Combination; and (16) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form F-1 and the prospectus included therein filed by Cazoo Group Ltd (f/k/a Capri Listco). The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the disclosure included in other documents filed by Cazoo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Cazoo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Cazoo gives no assurance that it will achieve its expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005198/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer11.8.2026 14:30:00 CEST | Press release
Suha Jhaveri, Bill Warren and Jim Wassil added to ILiAD Board of Directors; Antony Blanc appointed Chief Business OfficerAppointments deepen vaccine development expertise and enhance global commercial and strategic leadership ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the appointments of Jim Wassil, currently Chief Operating Officer at Vaxcyte; Suha Jhaveri, former Strategic Advisor at Cidara before its acquisition by Merck; and Bill Warren, former Global Head of Antigen Design at Sanofi Vaccines, as independent members of ILiAD’s Board of Directors. The Company also announced the appointment of Antony Blanc, former VP, Head of Global Marketing and Global Strategic Pricing at GSK Vaccines, as Chief Business Officer. “Our recently appointed colleagues bring an extraordinary depth of experience in vaccine development, global commercialization, and strate
TEC reduces pressure on support teams with proactive outage communications powered by Adtran and GOCare11.8.2026 14:15:00 CEST | Press release
News summary: Fiber broadband providers need faster, more transparent ways to manage outages and reduce support surges TEC is now using GOCare OutageIQ integrated with Adtran’s outage notification API and Mosaic One to automate subscriber messaging Open APIs turn network insight into actionable workflows, improving responsiveness and operational efficiency Adtran and GOCare today announced that Telephone Electronics Corporation (TEC) has improved outage responses and reduced inbound support tickets using GOCare’s OutageIQ solution integrated with Adtran’s outage notification API and Mosaic One. Serving communities across Mississippi, Alabama and Tennessee, TEC delivers fiber broadband services built on a foundation of community investment and reliable service. By combining proactive notifications with real-time network insights, the service provider can now inform customers as issues are detected while equipping support teams with immediate context. This transparency helps build subscr
Kinaxis-Sponsored Study Identifies Supply Chain AI Accountability Gap Amidst Rapid Adoption Expectations11.8.2026 14:07:00 CEST | Press release
Trust, measurable outcomes, and governance lag, even as 41% expect autonomous-at-scale operations within two years Kinaxis® (TSX:KXS), a global leader in supply chain orchestration, today announced the findings of new independent research from IDC. The IDC InfoBrief, sponsored by Kinaxis, “Making Supply Chain AI Accountable,” reveals a growing chasm between organizations’ aggressive ambitions for autonomous AI adoption and their readiness to hold these advanced systems - which we believe underscores the need for a disciplined approach to AI investment and deployment to prevent costly failures and deliver measurable business value. What This Means for Supply Chain Leaders The IDC InfoBrief, which surveyed more than 2,000 supply chain leaders across nine global markets, found that while AI adoption is nearly universal - only 2% of respondents report no AI-enabled capabilities, and just 12% consider themselves AI leaders. Over half (52%) cite trust in AI-driven decisions as a top barrier
One in Four Executives Say AI Errors Have Reached External Audiences or Boards, According to New Research From Workiva11.8.2026 14:00:00 CEST | Press release
Although 84% of executives are at least somewhat confident in AI output without human review, only 11% believe their data quality is sufficient for AI use Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, today released findings from its 2026 Midyear Executive Benchmark Survey. Although 84% of surveyed executives say they are at least somewhat confident in the accuracy of AI output without human review, one in four (26%) say internal audits have detected AI errors that reached external audiences or board members. This data suggests there is a disconnect between what executives believe and what evidence shows. As AI reshapes the enterprise at unprecedented speed, a new risk is emerging: transformation could be outpacing the instincts of the leaders tasked with overseeing it. "Confidence in AI without control over data quality is a liability, not a strategy. CFOs need platforms that connect AI to trusted, auditable data so every output
Altasciences Continues to Expand North American Bioanalytical Footprint11.8.2026 14:00:00 CEST | Press release
Altasciences today announced a major expansion of its North American bioanalytical laboratory footprint, reinforcing its commitment to helping sponsors accelerate drug development through increased capacity, advanced automation, and harmonized scientific operations. The expansion includes a 4,000-square-foot addition to the company’s laboratory in Greater Montréal, which is expected to be fully operational by the end of Q3 2026. The company has also announced a new 13,000-square-foot purpose-built laboratory in Harleysville, Pennsylvania. Construction will proceed in phases, with Phase 1 scheduled for completion in Q1 2027. These investments significantly increase Altasciences' ability to support the growing demand for late-stage clinical bioanalysis while providing sponsors with greater flexibility, scalability, and operational resilience. Designed to support increasingly complex development programs, the expanded laboratories will result in increased capacity to conduct larger studie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
